Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04636632 | Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03121716 | A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02775812 | Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03122496 | Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | completed | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| NCT03144778 | Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer | completed | Phase 1 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT03246659 | Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC(GRAN-T-MTC) | completed | Phase 1 | 16 | Paola Anna ErbaOTHER | 5 | Mar 20, 2020 | clinicaltrials |
| NCT01254617 | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer(ADCC) | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT01447056 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases(MALTED) | completed | Phase 1 | 37 | Baylor College of MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01445405 | Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02849314 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02849327 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03007836 | High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02953197 | 18F-FDG-PET Guided Dose-Painting With Intensity Modulated Radiotherapy in Oropharyngeal Tumours(FiGaRO) | completed | Phase 1 | 26 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT01064921 | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | completed | Phase 1 | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03876574 | Hepatic Artery Infusion Pump for NPC Liver Metastases | completed | Phase 1 | 16 | Xiangya Hospital of Central South UniversityOTHER | 0 | Mar 15, 2019 | clinicaltrials |
| NCT00318890 | Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 48 | University of Alabama at BirminghamOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01140178 | A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx | completed | Phase 1 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | completed | Phase 1 | 89 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01800071 | A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma | completed | Phase 1 | 22 | Cancer Research UKOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT02035527 | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 3 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01462474 | Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma(FMTN-I-LNPC) | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01534585 | Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 48 | Taizhou HospitalOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02456701 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | completed | Phase 1 | 7 | Celldex TherapeuticsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00431210 | Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00970502 | Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 15 | Johnny KaoOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)(NATELLA) | completed | Phase 1 | 23 | Baylor College of MedicineOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01921426 | A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | completed | Phase 1 | 30 | Galera Therapeutics, Inc.INDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT02523430 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT01413113 | Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery | completed | Phase 1 | 6 | University of WashingtonOTHER | 1 | Nov 5, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00706316 | Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer(NPC-CTL) | completed | Phase 1 | 5 | University Health Network, TorontoOTHER | 1 | Jul 10, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Dec 1, 2022source: clinicaltrials